PRAGUE MEDICAL REPORT, Vol 125 No 3 (2024), 187–194
Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients
Sara Merdita, Pavel Ryšánek, Jan Miroslav Hartinger, Ondřej Slanař, Martin Šíma
DOI: https://doi.org/10.14712/23362936.2024.18
zveřejněno: 22. 08. 2024
Abstract
Mycophenolate mofetil (MMF) is an immunosuppressant drug approved for prophylaxis of transplant rejection in patients undergoing solid organ transplantation and is further employed in management of various autoimmune disorders. MMF exhibits notable pharmacokinetic inter- and intraindividual variability necessitating tailored therapeutic approaches to achieve optimal therapeutic outcomes while mitigating risks of adverse effects. The objective of this review was to summarize factors that influence the pharmacokinetics of MMF and its active metabolite mycophenolic acid in order to deduce recommendations for personalized treatment strategies. Presumed predictors were analysed in relation to each of the four pharmacokinetic phases, providing tools and targets for MMF dosing optimization amenable to clinical implementation.
klíčová slova: Mycophenolate mofetil; Mycophenolic acid; Personalized medicine; Pharmacokinetics; Therapeutic drug monitoring;, Immunosuppressants
Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients is licensed under a Creative Commons Attribution 4.0 International License.
167 x 240 mm
vychází: 4 x ročně
cena tištěného čísla: 450 Kč
ISSN: 1214-6994
E-ISSN: 2336-2936